Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Nuclear Medicine and Molecular Imaging
Published in: Nuclear Medicine and Molecular Imaging 3/2024

Open Access 01-02-2024 | Breast Cancer | Original Article

Association Between 18F-FDG PET Activity and HER2 Status in Breast Cancer Brain Metastases

Authors: Jonathan R. Young, Julie A. Ressler, Joanne E. Mortimer, Daniel Schmolze, Mariko Fitzgibbons, Bihong T. Chen

Published in: Nuclear Medicine and Molecular Imaging | Issue 3/2024

Login to get access

Abstract

Purpose

The objective of this study was to evaluate whether uptake on 18F-fluorodeoxyglucose (18F-FDG) PET could help differentiate HER2-positive from HER2-negative breast cancer brain metastases.

Methods

In this retrospective, cross-sectional study of a cohort of 14 histologically proven breast cancer brain metastases, we analyzed both preoperative 18F-FDG PET/CT and HER2 status of the resected/biopsied brain specimens. The maximum standardized uptake values (SUVmax) of the lesions were normalized to contralateral normal white matter and compared using Mann–Whitney U tests.

Results

The study cohort was comprised of 12 women with breast cancer with a mean age of 59 years (range: 43–76 years) with a total of 14 distinct brain metastatic lesions. The SUVmax ratio of HER2-positive breast cancer brain metastases was significantly greater than that of HER2-negative lesions (3.98 vs 1.79, U = 38.00, p = 0.008).

Conclusion

The SUVmax ratio may help to identify the HER2 status of breast cancer brain metastases, if validated prospectively.
Literature
1.
Garcia-Alvarez A, Papakonstantinou A, Oliveira M. Brain metastases in HER2-positive breast cancer: current and novel treatment strategies. Cancers (Basel). 2021;13:2927.CrossRefPubMed
2.
Zimmer AS, Van Swearingen AED, Anders CK. HER2-positive breast cancer brain metastasis: a new and exciting landscape. Cancer Rep (Hoboken). 2020;5: e1274.CrossRefPubMed
3.
Martin AM, Cagney DN, Catalano PJ, Warren LE, Bellon JR, Punglia RS, et al. Brain metastases in newly diagnosed breast cancer: a population-based study. JAMA Oncol. 2017;3:1069–77.CrossRefPubMedPubMedCentral
4.
Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1–01). Lancet Oncol. 2013;14:244–8.CrossRefPubMed
5.
Lin NU, Amiri-Kordestani L, Palmieri D, Liewehr DJ, Steeg PS. CNS metastases in breast cancer: old challenge, new frontiers. Clin Cancer Res. 2013;19:6404–18.CrossRefPubMedPubMedCentral
6.
7.
Elias SG, Adams A, Wisner DJ, Esserman LJ, van T Veer LJ, et al. Imaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23:1464–83.CrossRefPubMed
8.
Marchiò C, Annaratone L, Marques A, Casorzo L, Berrino E, Sapino A. Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond. Semin Cancer Biol. 2021;72:123–5.CrossRefPubMed
9.
Giordano SH, Temin S, Chandarlapaty S, Crews JR, Esteva FJ, Kirshner JJ, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36:2736–40.CrossRefPubMed
10.
Cortés J, Kim S-B, Chung W-P, Im S-A, Park YH, Hegg R, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386:1143–54.CrossRefPubMed
11.
Yeh R-H, Yu J-C, Chu C-H, Ho C-L, Kao H-W, Liao G-S, et al. Distinct MR imaging features of triple-negative breast cancer with brain metastasis. J Neuroimaging. 2015;25:474–81.CrossRefPubMed
12.
Hadjipanteli A, Doolan P, Kyriacou E, Constantinidou A. Breast cancer brain metastasis: the potential role of MRI beyond current clinical applications. Cancer Manag Res. 2020;12:9953–64.CrossRefPubMedPubMedCentral
13.
Hoefnagel LDC, van de Vijver MJ, van Slooten H-J, Wesseling P, Wesseling J, Westenend PJ, et al. Receptor conversion in distant breast cancer metastases. Breast Cancer Res. 2010;12:R75–R75.CrossRefPubMedPubMedCentral
14.
Hulsbergen AFC, Claes A, Kavouridis VK, Ansaripour A, Nogarede C, Hughes ME, et al. Subtype switching in breast cancer brain metastases: a multicenter analysis. Neuro Oncol. 2020;22:1173–81.CrossRefPubMedPubMedCentral
15.
Thomson AH, McGrane J, Mathew J, Palmer J, Hilton DA, Purvis G, et al. Changing molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomes. Br J Cancer. 2016;114:793–800.CrossRefPubMedPubMedCentral
16.
Chang S, Chesney J, Trent JO, Telang S. Abstract 2519: Targeting glucose metabolism in HER2+breast cancer. Cancer Res. 2021;81:2519–619.CrossRef
17.
Farhadi P, Yarani R, Valipour E, Kiani S, Hoseinkhani Z, Mansouri K. Cell line-directed breast cancer research based on glucose metabolism status. Biomed Pharmacother. 2022;146: 112526.CrossRefPubMed
18.
Kim JY, Lee SH, Kim S, Kang T, Bae YT. Tumour 18 F-FDG uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes. Eur Radiol. 2015;25:1172–81.CrossRefPubMed
19.
Nitchingham A, Pereira JV, Wegner EA, Oxenham V, Close J, Caplan GA. Regional cerebral hypometabolism on 18F-FDG PET/CT scan in delirium is independent of acute illness and dementia. Alzheimers Dement. 2023;19:97–106.CrossRefPubMed
20.
Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. Arch Pathol Lab Med. 2018;142:1364–82.CrossRefPubMed
21.
Swain SM, Miles D, Kim S-B, Im Y-H, Im S-A, Semiglazov V, et al. End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). J Clin Oncol. 2019;37:1020–120.CrossRef
22.
Modi S, Saura C, Yamashita T, Park YH, Kim S-B, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2019;382:610–21.CrossRefPubMedPubMedCentral
23.
Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Phase III NALA Trial. J Clin Oncol. 2020;38:3138–49.CrossRefPubMedPubMedCentral
24.
Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020;38:2610–9.CrossRefPubMedPubMedCentral
25.
Linzer RW, Guida DL, Aminov J, Snider JM, Khalife G, Buyukbayraktar AB, et al. Dihydroceramide desaturase 1 (DES1) promotes anchorage-independent survival downstream of HER2-driven glucose uptake and metabolism. FASEB J. 2022;36: e22558.CrossRefPubMed
26.
Kyeong S, Cha YJ, Ahn SG, Suh SH, Son EJ, Ahn SJ. Subtypes of breast cancer show different spatial distributions of brain metastases. PLoS ONE. 2017;12: e0188542.CrossRefPubMedPubMedCentral
27.
Laakmann E, Witzel I, Scriba V, Grzyska U, Zu Eulenburg C, Burchardi N, et al. Radiological patterns of brain metastases in breast cancer patients: a subproject of the German Brain Metastases in Breast Cancer (BMBC) Registry. Int J Mol Sci. 2016;17:1615.CrossRefPubMedPubMedCentral
28.
Ahn SJ, Park M, Bang S, Cho E, Ahn SG, Suh SH, et al. Apparent diffusion coefficient histogram in breast cancer brain metastases may predict their biological subtype and progression. Sci Rep. 2018;8:9947.CrossRefPubMedPubMedCentral
29.
Ulu E, Ozturk B, Atalay K, Okumus IB, Erdem D, Gul MK, et al. Diffusion-weighted imaging of brain metastasis: correlation of MRI parameters with histologic type. Turk Neurosurg. 2022;32:58–68.PubMed
30.
Young JR, Ressler JA, Mortimer JE, Schmolze D, Fitzgibbons M, Chen BT. Performance of enhancement on brain MRI for identifying HER2 overexpression in breast cancer brain metastases. Eur J Radiol. 2021;144: 109948.CrossRefPubMed
31.
Young JR, Ressler JA, Mortimer JE, Schmolze D, Fitzgibbons M, Chen BT. Association of lesion contour and lesion composition on MR with HER2 status in breast cancer brain metastases. Magn Reson Imaging. 2023;96:60–6.CrossRefPubMed
32.
Young JR, Ressler JA, Shiroishi MS, Mortimer JE, Schmolze D, Fitzgibbons M, et al. Association of relative cerebral blood volume from dynamic susceptibility contrast-enhanced perfusion MR with HER2 status in breast cancer brain metastases. Acad Radiol. 2023;30:1816–22.CrossRefPubMed
Metadata
Title
Association Between 18F-FDG PET Activity and HER2 Status in Breast Cancer Brain Metastases
Authors
Jonathan R. Young
Julie A. Ressler
Joanne E. Mortimer
Daniel Schmolze
Mariko Fitzgibbons
Bihong T. Chen
Publication date
01-02-2024
Publisher
Springer Nature Singapore
Published in
Nuclear Medicine and Molecular Imaging / Issue 3/2024
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-024-00843-8

Other articles of this Issue 3/2024

Nuclear Medicine and Molecular Imaging 3/2024 Go to the issue

Case Report

First Local Experience of Intra-Cavitary Yttrium-90 Citrate Colloid Irradiation via Ommaya Reservoir for Refractory Cystic Craniopharyngioma: a Case Report

Original Article

Incidentally Detected Gallbladder Carcinoma: Can F-18 FDG PET/CT Aid in Staging and Prognostication?

Case Report

Annotating the Role of 18F-FDG PET/CT in Fibromatoses: A Benign Masquerader of Malignancies—Is It Really an Advantageous Tool?

Letter to editor

Contribution of ChatGPT in Parkinson’s Disease Detection

Editorial

Recent Updates on Applications of Artificial Intelligence for Nuclear Medicine Professionals: Prostate Cancer and PET/CT

Interesting image

Discordant Molecular Imaging Findings with 2-[18F]FDG and [68Ga]Ga-PSMA PET/CT in a Patient with Both Bladder and Prostate Cancer